AR078732A1 - Compuestos heterociclicos fusionados como moduladores del receptor de la orexina - Google Patents

Compuestos heterociclicos fusionados como moduladores del receptor de la orexina

Info

Publication number
AR078732A1
AR078732A1 ARP100103875A ARP100103875A AR078732A1 AR 078732 A1 AR078732 A1 AR 078732A1 AR P100103875 A ARP100103875 A AR P100103875A AR P100103875 A ARP100103875 A AR P100103875A AR 078732 A1 AR078732 A1 AR 078732A1
Authority
AR
Argentina
Prior art keywords
substituted
group
alkyl
unsubstituted
halo
Prior art date
Application number
ARP100103875A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR078732A1 publication Critical patent/AR078732A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Dichos compuestos pueden ser utiles en composiciones farmacéuticas y métodos para el tratamiento de estados anormales, trastornos y afecciones mediadas por la actividad de la orexina, tales como insomnio. Reivindicacion 1: Una entidad química que es un compuesto de Formula (1): en donde n es 0-1; R1 es un miembro seleccionado del grupo que consiste de: A) fenilo sustituido o no sustituido con Ra, y sustituido en la posicion orto con Rb; Ra es un miembro seleccionado independientemente del grupo que consiste de: halo, alquilo -C1-4, y alcoxi -C1-4; Rb es un miembro seleccionado del grupo que consiste de: a) halo o alcoxi -C1-4, b) tiofen-2-ilo, 2H-1,2,3-triazol, 1H-1,2,3-triazol-1-ilo, 1H-pirazol-1-ilo, 1H-pirazol-5-ilo, pirimidin-2-ilo, o 3-metil-1,2,4-oxadiazol-5-ilo, y c) fenilo; B) piridina sustituida o no sustituida con uno o dos miembros seleccionados independientemente del grupo que consiste de: alquilo C1-4 y 1H-1,2,3-triazol-1-ilo, en donde los sustituyentes están en una posicion adyacente al punto de union por R1; y C) metiltiazol sustituido con 2-fluorofenilo; R2 es un miembro seleccionado del grupo que consiste de: A) anillo de heteroarilo de 6 miembros que contiene dos miembros de nitrogeno sustituidos o no sustituidos con uno o más miembros seleccionados del grupo que consiste de: -alquilo C1-4, -alcoxi C1-4, -CF3, halo, -N(alquilo C1-4)2, -NH2, y fenilo; B) piridina sustituida o no sustituida con uno o más miembros seleccionados independientemente del grupo que consiste de: -CF3 y alquilo -C1-4; C) quinoxalin-2-ilo o quinolina sustituida o no sustituida con -alquilo C1-4; D) benzooxazol-2-ilo sustituido o no sustituido con halo; y E) 4-metil-6,7-dihidro-5H-ciclopenta[d]pirimidina; y sales aceptables farmacéuticamente de compuestos de la Formula 1.
ARP100103875A 2009-10-23 2010-10-22 Compuestos heterociclicos fusionados como moduladores del receptor de la orexina AR078732A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25451709P 2009-10-23 2009-10-23

Publications (1)

Publication Number Publication Date
AR078732A1 true AR078732A1 (es) 2011-11-30

Family

ID=43221929

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103875A AR078732A1 (es) 2009-10-23 2010-10-22 Compuestos heterociclicos fusionados como moduladores del receptor de la orexina

Country Status (10)

Country Link
US (1) US9062044B2 (es)
EP (1) EP2491031B1 (es)
JP (2) JP5848251B2 (es)
AR (1) AR078732A1 (es)
CL (1) CL2010001160A1 (es)
HK (1) HK1175462A1 (es)
PE (1) PE20110328A1 (es)
TW (1) TW201141859A (es)
UY (1) UY32967A (es)
WO (1) WO2011050202A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
US9062044B2 (en) * 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
TR201910327T4 (tr) 2009-10-23 2019-07-22 Janssen Pharmaceutica Nv Oreksin reseptör modülatörleri olarak di-ornatılmış oktahidropirrolo [3,4-c]pirroller.
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
DK2776430T3 (en) 2011-11-08 2016-05-09 Actelion Pharmaceuticals Ltd 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
HUE031753T2 (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
CN103012293A (zh) * 2012-12-13 2013-04-03 同济大学 一种抗失眠药物mk-4305中间体的合成方法
US9403813B2 (en) 2013-03-12 2016-08-02 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
EP3077391B1 (en) 2013-12-04 2018-08-15 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
JP6663909B2 (ja) 2014-08-13 2020-03-13 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
US9611262B2 (en) 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2017012502A1 (en) 2015-07-17 2017-01-26 Sunshine Lake Pharma Co., Ltd. Substituted quinazoline compounds and preparation and uses thereof
AU2016360245B2 (en) 2015-11-23 2020-07-09 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo [3, 4-c] pyrrole derivatives and uses thereof
EP3414241B1 (en) 2016-02-12 2022-05-04 Astrazeneca AB Halo-substituted piperidines as orexin receptor modulators
SI3426251T1 (sl) 2016-03-10 2022-07-29 Janssen Pharmaceutica Nv Postopki za zdravljenje depresije z antagonisti receptorja oreksina-2
PT3619199T (pt) 2017-05-03 2021-10-01 Idorsia Pharmaceuticals Ltd Preparação de derivados de ácido 2-([1,2,3]triazol-2-il)- benzoico
CN113164459B (zh) 2018-09-28 2024-09-03 詹森药业有限公司 单酰基甘油脂肪酶调节剂
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子
KR20210091726A (ko) * 2018-11-14 2021-07-22 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 융합 헤테로사이클릭 화합물을 제조하는 개선된 합성 방법
JP2022550767A (ja) 2019-09-30 2022-12-05 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375897B1 (en) 2000-02-14 2002-04-23 Ansys Technologies, Inc. Urine collection cup
MY137020A (en) * 2000-04-27 2008-12-31 Abbott Lab Diazabicyclic central nervous system active agents
US6809105B2 (en) 2000-04-27 2004-10-26 Abbott Laboratories Diazabicyclic central nervous system active agents
EP1399441B1 (en) 2001-06-28 2006-07-05 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB2383315B (en) 2001-12-18 2005-04-06 Christopher Donald Clarke Vehicle imaging system
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
AU2003246657A1 (en) 2002-07-09 2004-01-23 Actelion Pharmaceuticals Ltd. 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives
JP4528125B2 (ja) 2002-10-11 2010-08-18 アクテリオン ファーマシューティカルズ リミテッド スルホニルアミノ−酢酸誘導体
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US20040242641A1 (en) 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
EP1846409A1 (en) 2004-11-24 2007-10-24 Pfizer Limited Octahydropyrrolo[3,4-c]pyrrole derivatives
DE102004061344A1 (de) 2004-12-20 2006-07-06 Siemens Ag Verfahren zur sicheren Auslegung eines Systems, zugehörige Systemkomponente und Software
WO2006124897A2 (en) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Methods and compositions for improving cognition
ZA200709626B (en) 2005-05-13 2009-02-25 Lexicon Pharmaceuticals Inc Multicyclic compounds and methods of their use
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
US20090176789A1 (en) * 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
EP2001485B1 (en) 2006-03-29 2015-09-09 Merck Sharp & Dohme Corp. Diazepan orexin receptor antagonists
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
WO2008008551A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
CA2657552A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Substituted diazepan orexin receptor antagonists
JP2010503714A (ja) 2006-09-18 2010-02-04 エフ．ホフマン−ラ ロシュ アーゲー オクタヒドロピロロ［３，４−ｃ］ピロール誘導体、抗ウイルス剤としてのそれらの使用
CA2668811A1 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US8263586B2 (en) 2007-05-18 2012-09-11 Merck Sharp & Dohme Corp. OXO bridged diazepan orexin receptor antagonists
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
US20110263662A1 (en) 2007-08-15 2011-10-27 Hamed Aissaoui 1,2-diamido-ethylene derivatives as orexin antagonists
CA2703904A1 (en) 2007-10-29 2009-05-07 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
EP2058001A1 (en) 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Enhancement of immunogenicity of antigens
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
PE20091157A1 (es) 2007-12-21 2009-09-03 Astrazeneca Ab Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
US8129384B2 (en) 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
EP2350066B1 (en) 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
AU2009307916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
JP2012506377A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，４−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
WO2010048017A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
AU2009307915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
PE20110852A1 (es) 2008-10-30 2011-11-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
AU2009308982A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
WO2010051237A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
AU2009324239A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US9062044B2 (en) * 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators

Also Published As

Publication number Publication date
US20130137672A1 (en) 2013-05-30
JP2013508405A (ja) 2013-03-07
JP5848251B2 (ja) 2016-01-27
TW201141859A (en) 2011-12-01
JP2016102118A (ja) 2016-06-02
HK1175462A1 (en) 2013-07-05
US9062044B2 (en) 2015-06-23
EP2491031B1 (en) 2013-08-07
UY32967A (es) 2011-04-29
EP2491031A1 (en) 2012-08-29
WO2011050202A1 (en) 2011-04-28
PE20110328A1 (es) 2011-06-09
CL2010001160A1 (es) 2011-03-25
JP6170121B2 (ja) 2017-07-26

Similar Documents

Publication Publication Date Title
AR078732A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de la orexina
AR078733A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de orexina
NZ716420A (en) Fused heterocyclic compounds as sodium channel modulators
AR078731A1 (es) Octahidropirrolo (3,4-c) pirroles disustituidos como moduladores del receptor de orexina
US9499495B2 (en) Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
AR078228A1 (es) Inhibidores de cyp17
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
MY148322A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
MY158193A (en) Morpholino pyrimidines and their use in therapy
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
PE20160540A1 (es) Inhibidores de bromodominios
IN2014DN03063A (es)
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
EA201101186A1 (ru) Конденсированные пиримидины
MX2015014861A (es) Pirimidinas sustituidas con heterocicloalquilo c-enlazado y sus usos.
NZ596117A (en) Novel anti-inflammatory agents
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
PE20130386A1 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
EA201390022A8 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure